Cardiogen Peptide

Cardiac tetrapeptide normalizing myocardial cell gene expression. Research demonstrates improved contractile function, reduced fibrosis, enhanced mitochondrial efficiency, and normalized calcium handling in aging heart models.

Cardiogen (Ala-Glu-Asp-Arg) is a short synthetic tetrapeptide belonging to the Khavinson family of cytogenic bioregulators. Like other peptides in this class (Epithalon, Vilon, Bronchogen, Chonluten), Cardiogen is hypothesized to function as a gene-regulatory ligand whose ultra-low molecular weight (~516 Da) and balanced acidic/basic residue composition allow penetration across cellular and nuclear membranes. Once intracellular, the tetrapeptide is proposed to interact directly with DNA double helices in promoter regions of tissue-specific genes, modulating transcription in cardiomyocytes and vascular endothelial cells.

DNA-Binding and Epigenetic Modulation

Research on related Khavinson peptides demonstrates sequence-selective binding to CpG-rich promoter sites. For Cardiogen, in vitro studies suggest preferential interaction with promoters of genes encoding myocardial contractile proteins, antioxidant enzymes, and anti-apoptotic regulators. This binding is thought to displace methylated CpG silencing complexes, allowing renewed transcription of genes that are downregulated during cardiomyocyte senescence. The result is a normalization of the cardiomyocyte transcriptome toward a more youthful expression profile.

Restoration of Cardiomyocyte Function

In aging myocardium, calcium handling proteins (SERCA2a, phospholamban, ryanodine receptor) progressively decline, contributing to impaired contractility and diastolic dysfunction. Preclinical models indicate that Cardiogen administration partially restores expression of these calcium-cycling components, improving Ca²⁺ reuptake and sarcomere relaxation kinetics. Additionally, mitochondrial biogenesis markers (PGC-1α, TFAM) appear upregulated, supporting ATP production required for sustained myocardial workload.

Antioxidant and Anti-Apoptotic Pathways

Cardiogen has been associated with upregulation of endogenous antioxidant defenses, including superoxide dismutase (SOD) and glutathione peroxidase (GPx). This reduces accumulation of reactive oxygen species (ROS) that drive ischemic and aging-related cardiomyocyte damage. Concurrently, the peptide modulates Bcl-2/Bax balance toward an anti-apoptotic state, reducing programmed cell death following oxidative or ischemic insult in experimental models.

Vascular Endothelial Effects

Beyond cardiomyocytes, Cardiogen research suggests activity on vascular endothelium. Endothelial nitric oxide synthase (eNOS) expression and NO bioavailability appear preserved or enhanced, supporting vasodilation, anti-thrombotic surface properties, and reduced leukocyte adhesion. This dual myocardial–vascular activity differentiates Cardiogen from peptides targeting cardiomyocytes alone.

Comparison to Related Bioregulators

Whereas Epithalon (Ala-Glu-Asp-Gly) is studied primarily for pineal telomerase induction, and Vilon (Lys-Glu) for thymic immune restoration, Cardiogen's Ala-Glu-Asp-Arg sequence appears optimized for cardiac tissue tropism. The substitution of arginine for glycine (relative to Epithalon) is hypothesized to confer affinity for cardiac-specific gene promoters, although the exact recognition motif remains under investigation. Collectively, these mechanisms position Cardiogen as a research tool for studying transcriptional approaches to cardiac aging and stress resilience.

Cardiogen is a short synthetic tetrapeptide with the sequence Ala-Glu-Asp-Arg (AEDR). Its low molecular weight and balanced acidic (Glu, Asp) and basic (Arg) residue composition characterize it as a member of the Khavinson cytogenic bioregulator family. Below are the verified chemical and physical properties relevant for laboratory handling and reconstitution.

Structural Notes

Cardiogen contains no cysteine residues and therefore no disulfide bonds, simplifying handling relative to peptides like Thymosin Alpha-1 or BPC-157 derivatives. The absence of methionine eliminates oxidation concerns common to longer peptides. The N-terminal alanine and free C-terminal arginine carboxylate provide a stable, unprotected linear backbone. The arginine guanidinium group is the most basic functionality and the primary site of protonation in aqueous solution, contributing to the peptide's high aqueous solubility.

Cardiogen (Ala-Glu-Asp-Arg) is supplied as a sterile lyophilized powder. Its small size (tetrapeptide, MW 516.51 g/mol) and absence of cysteine residues, methionine, or tryptophan make it relatively stable during reconstitution, though standard peptide handling protocols should always be observed in research settings.

Recommended Reconstitution Protocol

1. Equilibrate vials: Allow the sealed lyophilized vial to reach room temperature (approximately 15–20 minutes) before opening to prevent condensation of atmospheric moisture onto the dry peptide cake.
2. Select diluent: Bacteriostatic water for injection (0.9% benzyl alcohol) is suitable for most laboratory reconstitution. Sterile water for injection or sterile saline (0.9% NaCl) may also be used, particularly for short-term studies.
3. Calculate concentration: A common working stock is 5 mg of peptide reconstituted in 1 mL of diluent to yield a 5 mg/mL solution. For 10 mg vials, 2 mL of diluent yields the same 5 mg/mL concentration.
4. Add diluent gently: Inject the diluent slowly down the inner wall of the vial — never directly onto the peptide cake. Mechanical force can degrade short peptides through localized denaturation.
5. Dissolve by swirling: Gently swirl or rotate the vial until the powder dissolves completely. This typically occurs within 30–60 seconds for Cardiogen due to its high solubility in aqueous media. Do not shake or vortex aggressively — this can introduce foaming and air-water interface denaturation.
6. Visual inspection: The reconstituted solution should be clear and colorless. Discard any vial showing particulate matter, turbidity, or discoloration.

Compound-Specific Handling Notes

• Charged residues: The sequence contains glutamate (Glu), aspartate (Asp), and arginine (Arg), giving the peptide multiple ionizable groups. Reconstitution in solutions of extreme pH should be avoided, as deamidation of Asn/Gln-like residues and acid-catalyzed hydrolysis can occur. Neutral aqueous diluents (pH 5–7) are optimal.
• No disulfide bonds: Unlike cyclic peptides, Cardiogen has no disulfide bridges, eliminating concerns about reduction or scrambling during handling.
• Aseptic technique: Use sterile syringes and work in a laminar flow hood when preparing solutions for in vitro studies to prevent microbial contamination.
• Aliquoting: For long-term studies, divide the reconstituted stock into single-use aliquots in low-binding microcentrifuge tubes to avoid repeated freeze-thaw cycles.

All handling should be conducted by qualified research personnel using appropriate personal protective equipment. Cardiogen is intended strictly for in vitro and laboratory research applications.

Proper storage of Cardiogen (Ala-Glu-Asp-Arg) is essential to maintain peptide integrity and experimental reproducibility. Although the tetrapeptide is chemically simple and lacks oxidation-sensitive residues such as methionine, cysteine, or tryptophan, standard cold-chain practices for research peptides should be observed.

Lyophilized Powder Storage

• Long-term storage (recommended): Store the sealed lyophilized vial at -20°C or colder. Under these conditions, Cardiogen is expected to remain stable for at least 24 months from the date of manufacture, based on stability data typical for short non-modified peptides.
• Short-term storage: Storage at 2–8°C (standard refrigeration) is acceptable for up to several weeks if the vial remains sealed and protected from moisture.
• Transit/ambient exposure: Brief exposure to room temperature (up to 7–14 days) during shipping does not materially degrade the lyophilized peptide, which is one advantage of small tetrapeptides over larger, more labile compounds.
• Protect from moisture: Always store with desiccant if possible, and ensure the vial stopper is intact. Atmospheric moisture absorption is the primary degradation route for lyophilized peptides during storage.

Reconstituted Solution Storage

• Refrigerated (2–8°C): Reconstituted Cardiogen in bacteriostatic water remains stable for approximately 3–4 weeks when stored refrigerated and handled aseptically.
• Frozen aliquots (-20°C or -80°C): For longer storage of reconstituted material, aliquot into single-use volumes and freeze. Stability extends to 6 months or longer at -80°C. Avoid repeated freeze-thaw cycles, which can cause aggregation and loss of activity.
• Room temperature: Reconstituted solution should not be left at ambient temperature for extended periods, as hydrolysis and microbial growth become concerns.

Compound-Specific Stability Notes

• No methionine or cysteine: Cardiogen lacks the sulfur-containing residues that drive oxidative degradation in many peptides. This conveys excellent oxidative stability and reduces requirements for inert-gas storage.
• Light sensitivity: Cardiogen contains no aromatic residues (no Trp, Tyr, or Phe), making it largely insensitive to photodegradation. However, amber or opaque vials are still preferred as standard practice.
• Hydrolytic stability: The peptide bonds in this sequence are not preferentially susceptible to enzymatic or chemical hydrolysis under neutral conditions. Acidic or alkaline solutions should be avoided.
• Indicators of degradation: Discoloration, precipitation, or unexpected odor in either lyophilized or reconstituted material indicates degradation — discard and replace with fresh stock.

Following these storage guidelines ensures that experimental results remain reproducible and that the peptide retains its specified ≥98% purity throughout the research timeline.